1 recruiting, 1 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
Follow EGFR Sensitive Mutation: new trials by email Literature Review of EGFR Sensitive Mutation trials Research Report on EGFR Sensitive Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody Anlotinib, Penpulimab - Lung Cancer, TKI Resistance | Phase 3 | Unknown | Degan Lu | 52 | 2023-09-01 | 2023-09-21 |
| Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo - Non-Small Cell Lung Cancer, EGFR Sensitive Mutation | Phase 3 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 570 | 2023-03-28 | 2023-09-22 |
Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1)
Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Neoplasms (1)
anlotinib (1) · icotinib (1) · penpulimab (1)
Betta Pharmaceuticals Co., Ltd. (1) · Degan Lu (1)
China (1)
Shun Lu, M.D. (1)
PMID 27413711, PMID 28486985, PMID 29438373, PMID 30419091, PMID 33433946, PMID 33791214, PMID 34327136, PMID 35875118